ROR gamma t inverse agonist - Bristol-Myers Squibb
Alternative Names: RORγt inverse agonistLatest Information Update: 28 Feb 2021
At a glance
- Originator Exelixis
- Developer Bristol-Myers Squibb
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders